Arrhythmias & electrophysiology
Time to benefit and harm of direct oral anticoagulants in device-detected atrial fibrillation: A pooled analysis of the NOAH-AFNET 6 and ARTESiA trials
Pooled result · StrokeResult — go to the resultHazard ratio 0.67 95% CI 0.50–0.90Authors' conclusion
In elderly patients with low durations of DD-AFib, DOACs result in a delayed and restricted stroke-preventive benefit while posing an early-onset bleeding risk.
Study context
- Population
- Adults with device-detected AF (mean age >75 years; median atrial high-rate episode duration 1.5 to 2.8 hours)
- Participants
- 6,548 adults2 RCTs
- Comparison
- Direct oral anticoagulants (DOACs) vs no DOAC in device-detected AF
- Outcome
- Time to first stroke (efficacy); time to first major bleeding (safety)
Methodological detailsreconstructed patient-level data, Weibull model and Markov chain Monte Carlo simulation, Studies identified from PubMed until November 2023
- Reconstructed patient-level data
- Weibull model and Markov chain Monte Carlo simulation
- Studies identified from PubMed until November 2023
Pooled result
Stroke
Hazard ratio
0.67
95% CI 0.50–0.90
DOACsvs no DOAC in device-detected AF
HR 0.67 (95% CI 0.50–0.90)
As reported in the abstract
- Time to benefit (TTB) to prevent 1 stroke per 100 DOAC-treated patients
- 2.67 years
Safety
Major bleeding
| HR (95% CI) | ||
|---|---|---|
| DOACs | 1.57 (1.21–2.04) | |
| 0.512Hazard ratio (log scale) |
- Major bleeding — time to harm (TTH) to observe 1 major bleeding
- 1.67 years
Original publication
Time to benefit and harm of direct oral anticoagulants in device-detected atrial fibrillation: A pooled analysis of the NOAH-AFNET 6 and ARTESiA trials. Heart Rhythm. Published 24 June 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →